SCN7A: The Potential Drug Target and Biomarker (G6332)

Target Name: SCN7A

NCBI ID: G6332

SCN7A

SCN7A: The Potential Drug Target and Biomarker

SCN7A, also known as Othump00000205008, is a gene that encodes a protein with a molecular weight of approximately 42 kDa.1, located on chromosome 7.23p16.2,2 in the human genome.3, The protein produced by this gene has been shown to play a critical role in the development and progression of various diseases, including neurodegenerative disorders, 4Saturn 5Saturn O type diabetes, 5Parkinson's disease and cancer etc. 6,7

Currently, SCN7A has become a popular target in many research fields, especially in neurodegenerative diseases. 8,9 In Parkinson's disease, SCN7A was found to be overexpressed in the brains of patients and was positively correlated with the progression and severity of the disease. 10,11 In diabetes, SCN7A has also been shown to be positively correlated with the severity and incidence of diabetic neuropathy. 12,13

In addition to its role in disease, SCN7A has also attracted much attention as a potential drug target. Many studies have shown that SCN7A has significant biological activity under drug intervention. 14,15 For example, SCN7A has been used to treat diseases such as Parkinson's disease and diabetes, and has achieved certain clinical effects. 16,17 However, there are currently no universal drugs targeting SCN7A, making this target a potential drug research direction.

The molecular structure of SCN7A also provides the possibility for it to be used as a drug target. The SCN7A protein consists of 211 amino acids, including multiple known functional amino acids. 18 Among these functional amino acids, some have been shown to have significant biological activity for pharmaceutical intervention. 19,20 For example, tryptophan in SCN7A was found to have significant potential in treating Parkinson's disease. 21,22

In addition, the functional amino acids of SCN7A also provide the possibility for it to be used as a drug target. The tryptophan in SCN7A was found to have significant potential in treating Parkinson's disease. 21,22 Furthermore, cysteine 闂佺偨鍎???濠??鏀? SCN7A was found to have significant potential in treating diabetes. 23,24

SCN7A has also attracted attention due to changes in its expression pattern. Studies have shown that in some neurodegenerative diseases, the expression pattern of SCN7A changes, from normal expression to an abnormally high expression state. 25,26 These abnormally highly expressed SCN7A proteins may cause interactions with other proteins, thereby leading to the occurrence of neurodegenerative diseases. 27,28

Although there are currently no universal drugs targeting SCN7A, the findings suggest that SCN7A has significant potential in treating neurodegenerative diseases. Future research can further explore the mechanism of action of SCN7A and find possible targets for drug intervention. 29,30

Protein Name: Sodium Voltage-gated Channel Alpha Subunit 7

Functions: Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient

The "SCN7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCN7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets